Type I interferon receptor complex – Janus kinase – Signal transducer and activator of transcription pathway (IFNAR-JAK-STAT)

The Type I interferon receptor complex (IFNAR) and its associated JAK-STAT signaling pathway constitute a primary defense mechanism against viral infections and a key regulator of immune homeostasis. The receptor is a transmembrane heterodimer consisting of two subunits, IFNAR1 and IFNAR2, which bind to Type I interferons such as IFN-alpha and IFN-beta (Samuel, 2001, Clin Microbiol Rev). Upon ligand binding, the receptor-associated Janus kinases, JAK1 and TYK2, undergo cross-phosphorylation and subsequently phosphorylate Signal Transducer and Activator of Transcription (STAT) proteins, primarily STAT1 and STAT2 (StatPearls, 2023). These phosphorylated STATs dimerize and associate with IRF9 to form the ISGF3 complex, which translocates to the nucleus to drive the expression of hundreds of interferon-stimulated genes (ISGs) that mediate antiviral, pro-apoptotic, and anti-proliferative effects. Dysregulation of this pathway is a hallmark of various diseases; overactivation is linked to autoimmune conditions like systemic lupus erythematosus (SLE), while impaired signaling can lead to severe viral susceptibility or malignancy (Morand et al., 2020, N Engl J Med). Therapeutic interventions include recombinant interferon agonists for treating chronic hepatitis and certain cancers, as well as inhibitors like the anti-IFNAR1 antibody anifrolumab and small-molecule JAK/TYK2 inhibitors to treat autoimmune and inflammatory disorders (Mease et al., 2022, N Engl J Med).

Other names

Type I interferon signaling axisIFN-alpha/beta receptor signaling pathwayIFNAR-JAK-STAT axisType I IFN signaling cascade

The pathway is modulated through three primary mechanisms: agonism using recombinant Type I interferons to stimulate antiviral and anti-tumor responses; antagonism using monoclonal antibodies (e.g., anifrolumab) to block the IFNAR1 subunit and prevent ligand binding; and intracellular inhibition using small-molecule Janus kinase (JAK) inhibitors to block the phosphorylation of STAT proteins, thereby preventing the transcription of inflammatory genes.